Global guideline on pregnancy and diabetes - International ...
Global guideline on pregnancy and diabetes - International ...
Global guideline on pregnancy and diabetes - International ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<str<strong>on</strong>g>Global</str<strong>on</strong>g> Guideline <strong>on</strong> Pregnancy <strong>and</strong> Diabetes<br />
If further pregnancies are planned, then a repeat OGTT<br />
prior to c<strong>on</strong>cepti<strong>on</strong> or at least in the first trimester is<br />
desirable. If no abnormality is present, then testing should<br />
be repeated at the usual time <strong>and</strong> with the usual indicati<strong>on</strong>s<br />
during <strong>pregnancy</strong>.<br />
If no further pregnancies are planned, the l<strong>on</strong>g-term<br />
follow-up arrangements will depend heavily <strong>on</strong> the perceived<br />
risk of developing type 2 <strong>diabetes</strong>. In a high-risk<br />
group there should be an annual OGTT. In a low-risk<br />
group there could be fasting glucose every two to three<br />
years <strong>and</strong> an OGTT <strong>on</strong>ly if this level is ≥5.5 mmol/l<br />
(100 mg/dl).<br />
risk reducti<strong>on</strong> in the troglitaz<strong>on</strong>e treated group compared<br />
with placebo [114]. This beneficial effect was substantiated<br />
in the follow-<strong>on</strong> Pioglitaz<strong>on</strong>e in Preventi<strong>on</strong> of Diabetes<br />
(PIPOD) study when pioglitaz<strong>on</strong>e was substituted [115].<br />
The sec<strong>on</strong>d study was the Diabetes Preventi<strong>on</strong> Program<br />
(DPP), where women with previous GDM were included<br />
[116]. This study dem<strong>on</strong>strated a significant reducti<strong>on</strong> in<br />
type 2 <strong>diabetes</strong> for both lifestyle modificati<strong>on</strong> <strong>and</strong> metformin<br />
therapy compared with placebo. A subsequent<br />
sub-group analysis of the results found that, for women<br />
with previous GDM, lifestyle modificati<strong>on</strong> <strong>and</strong> metformin<br />
were equally effective [117].<br />
5.3 Preventi<strong>on</strong> of type 2 <strong>diabetes</strong> in women who<br />
developed GDM<br />
Women with previous GDM are at very high risk of<br />
developing type 2 <strong>diabetes</strong> [113]. The rate of c<strong>on</strong>versi<strong>on</strong><br />
will depend <strong>on</strong> a mixture of community <strong>and</strong> genetic<br />
factors. The preventi<strong>on</strong>, or at least delay in the development,<br />
of type 2 <strong>diabetes</strong> is an attractive opti<strong>on</strong>, as<br />
it is likely to reduce the risks associated with having<br />
established <strong>diabetes</strong>.<br />
There are several <strong>diabetes</strong> preventi<strong>on</strong> studies, all with<br />
positive outcomes. Two studies have targeted women<br />
with previous GDM. The first was the Troglitaz<strong>on</strong>e in<br />
Preventi<strong>on</strong> of Diabetes (TRIPOD) study that exclusively<br />
enrolled women with previous GDM <strong>and</strong> showed a 55%<br />
17<br />
Pregnancy_EN2.indd 17 16/09/09 15:42